BUZZ-Ascentage rises on progress of olverembatinib for blood cancer treatment** Shares of Ascentage Pharma Group International 6855.HK rise 6.8% to HK$65, their highest level since November 27
** Stock on track for the biggest one-day pct gain since August 5
** Ascentage receives clearance from US FDA and European Medicines Agency for a phrase III (POLARIS-1) study of its blood cancer drug olverembatinib
** The POLARIS-1 trial is a global, multicenter, randomized controlled, open-label study designed to evaluate the efficacy and safety of olverembatinib in combination with chemotherapy in newly diagnosed patients with certain types of leukemia
** Stock up 37% YTD; Hang Seng Biotech Index .HSBIO up 78.8%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments